Related Experiment Video
Updated: Jan 7, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
10.1K
Drug Development
Nicolo Foppa Pedretti1, Yashmin Karten1, Yi Zhang1
1Critical Path Institute, Tucson, AZ, USA.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 25, 2025
Summary
Autosomal dominant Alzheimer's disease (ADAD) trials reveal distinct tau accumulation patterns in mutation carriers. These findings offer insights into early disease progression and neurodegenerative mechanisms for both ADAD and sporadic Alzheimer's disease.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Autosomal dominant Alzheimer's disease (ADAD) presents unique drug development challenges.
- Cognitively healthy individuals with ADAD offer a model for studying early sporadic Alzheimer's disease (AD).
- The CPAD consortium aims to accelerate AD drug development by integrating clinical and observational data.
Purpose of the Study:
- To model drug-disease-trial dynamics for ADAD.
- To investigate tau and amyloid pathologies in early AD.
- To understand biomarker-cognition relationships and disease progression.
Main Methods:
- Utilized data from the Alzheimer's Prevention Initiative ADAD Colombia Trial.
- Employed a placebo-controlled clinical trial of crenezumab in PSEN1 E280A kindred members.
- Applied linear mixed-effect models to analyze longitudinal outcomes and regional tau/amyloid PET data.
Main Results:
- Identified distinct regional tau accumulation patterns in ADAD mutation carriers versus non-carriers.
- Observed variations in baseline amyloid dynamics and demographic effects on tau accumulation.
- Differentiated cognitive progression characteristics between ADAD and sporadic AD, revealing neurodegenerative mechanisms.
Conclusions:
- Characterized unique tau accumulation patterns and amyloid-tau interactions in ADAD mutation carriers.
- Provided insights into early disease progression and neurodegenerative mechanisms for ADAD and sporadic AD.
- Validated a robust framework for advancing therapeutic research in Alzheimer's disease.
More Related Videos
08:04In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
Published on: May 11, 2021
3.3K
05:45Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
Published on: October 10, 2025
451
Related Concept Videos
01:28Preclinical Development: Overview
5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
01:11Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
01:26Drug Discovery: Overview
10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
01:26Drug Administration and Therapy Phases: Overview
1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
01:10In Vitro Drug Release Testing: Overview, Development and Validation
279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
01:25Drug Regulation
2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K